SCHEMBL13664116

SCHEMBL13664116

COOSCCNCc1ccc(-c2cc3nccc(Oc4ccc(NC(=S)NC(=O)Cc5ccccc5)cc4F)c3s2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 20/20 0.68
KDR P35968 20/20 0.68
AURKA O14965 1/20 0.64
FPR1 P21462 1/20 0.64
FPR3 P25089 1/20 0.64
GPR183 P32249 1/20 0.64
SMO Q99835 1/20 0.64
GPR35 Q9HC97 1/20 0.64
PLK4 O00444 1/20 0.64
MAP4K4 O95819 1/20 0.64
ABL1 P00519 1/20 0.64
LCK P06239 1/20 0.64
FYN P06241 1/20 0.64
LYN P07948 1/20 0.64
HCK P08631 1/20 0.64
PDGFRB P09619 1/20 0.64
BCR P11274 1/20 0.64
SRC P12931 1/20 0.64
AXL P30530 1/20 0.64
FLT3 P36888 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13664111 0.96 MET (0.69) METKDRAURKAFPR1FPR3
SCHEMBL13664114 0.96 MET (0.70) METKDRAURKAFPR1FPR3
SCHEMBL13664112 0.93 MET (0.67) METKDRAURKAFPR1FPR3
SCHEMBL2670906 0.92 MET (0.71) METKDRAURKAFPR1FPR3
SCHEMBL3570352 0.90 MET (0.77) METKDRAURKAFPR1FPR3
SCHEMBL3567343 0.90 MET (0.73) METKDRAURKAFPR1FPR3
SCHEMBL3577604 0.90 MET (0.77) METKDRAURKAFPR1FPR3
SCHEMBL2671194 0.88 MET (0.70) METKDRAURKAFPR1FPR3
SCHEMBL2670780 0.88 MET (0.71) METKDRAURKAFPR1FPR3
SCHEMBL3570201 0.86 MET (0.74) METKDRAURKAFPR1FPR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8404846-B2 Inhibitors of protein tyrosine kinase activity METHYLGENE INC. (CA) 2013-03-26 US disclosed
US-20090264440-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY Mirati Therapeutics, Inc. 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264440-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY HGF, ERBB2, MET MET 3/4885KDR 11/4885AURKA 535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.